

PHARMING ANNOUNCES ISSUE OF SHARES UNDER AGREEMENTS

Leiden, The Netherlands, January 02, 2006. Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today the issue of 603,499 shares under issued warrant and other agreements and exercise of employee options.

The transactions provide Pharming with EUR 2.1 million in cash. The number of outstanding shares of the Company after the issue is 80.7 million. Furthermore, Pharming will publish its annual accounts 2005 on February 17, 2006.

Background on Pharming Group N.V.

Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for use in functional foods. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, <http://www.pharming.com>.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Anne Louise van Lynden
Investor Voice
T: +31 (0)71 524 7431

Sarah MacLeod
Financial Dynamics
T: +44 (0)7747 602 739

Samir Singh
Pharming Group N.V.
T: +1 908 720 6224
T: +1 800 333 1476